Join a Parkinson’s Study Without Ever Leaving Your Home

Did you know that people with Parkinson's disease (PD) have a higher risk of fractures?

Help us find a solution.
The TOPAZ study will test if a medicine called zoledronate can prevent fractures in people with PD. A team of doctors who are experts in bone health and PD are leading the study. The use of zoledronate in this study is investigational.

You can join if:

  • You have Parkinson's disease or Parkinsonism
  • Are 60 year old or older

The study is done from your home!

  • If you are eligible for the study, a nurse will come to your home to give you a short exam.
  • You'll receive a one-time dose of the study treatment (either zoledronate or a placebo)
  • During the study, we will contact you every four months to check if you have had any new fractures

Earn $100 upon enrollment and $50 per year during the study.

Want to learn more about joining TOPAZ? Visit the website or call the Parkinson's Foundation Helpline at 1-800-4PD-INFO (473-4636).

This study is endorsed by the Parkinson's Foundation and the Parkinson's Study Group.

PF          PSG

Learn more about PD and bone health.


Sign Up for Our E-Newsletter

Get the latest news about PD research, resources and community initiatives – straight to your inbox.

Please enter a valid email

Skip step

Invalid year format. Eg: 2020
Skip step
Zip code is required for chapter communications
Skip step

*Please note that not all content is available in both languages. If you are interested in receiving Spanish communications, we recommend selecting “both" to stay best informed on the Foundation's work and the latest in PD news.

Skip step

Thanks for Signing Up

We are proud to have you as a part of our community. To ensure you receive the latest Parkinson’s news, research updates and more, please check your email for a message from us. If you do not see our email, it may be in your spam folder. Just mark as “not spam” and you should receive our emails as expected.

mail icon

Subscribe here to get the latest news on treatments, research and other updates.